Low persistence with oral biphosphonate treatment in postmenopausal osteoporosis

Carla Torre, José Guerreiro, Zilda Mendes, Ana Miranda, Fátima Bragança, Joaquim Cristino, Helena Canhão, Jaime C Branco

Research output: Contribution to journalArticle

1 Downloads (Pure)

Abstract

BACKGROUND: Osteoporotic fractures are a major cause of morbidity and mortality. It is recognized that persistence with medication is crucial to reach optimal clinical outcomes. We aimed to estimate the persistence level to weekly and monthly oral bisphosphonates (OBP) in women with postmenopausal osteoporosis (PMO) over 24 months from therapy initiation in a population-based setting.

METHODS: Prospective observational cohort study of PMO women ≥50 years initiating OBP recruited through community pharmacies. Data were collected at baseline during face-to-face interviews. Follow-up included pharmacy records (refill dates and medication possession; cohort 1) and telephone-surveys for patients who agreed to be interviewed (cohort 2). Patients were classified as persistent if they refilled their prescription within 30 days after exhausting the time covered by their previous supply. Log-rank tests were used to compare Kaplan-Meier curves of time to non-persistence.

RESULTS: Of 427 women recruited with a mean age of 65.0 years, 380 (89%) agreed to be interviewed (cohort 2). Over 24-months of follow-up, 3.4% (95% CI: [2.0%; 5.6%]) of all subjects were persistent to OBP based on pharmacy records. Analysis combining both self-reported information and pharmacy records (cohort 2) showed a persistence estimate of 20.0% (95% CI: [16.1%; 24.2%]). Lower persistence was associated with more frequent OBP dosing and living alone. The most common reason for treatment discontinuation was self-reported adverse events (27.6%).

CONCLUSIONS: Results indicate a low level of persistence with OBP. Barriers and reasons leading to discontinuation of anti-PMO therapies should be proactively addressed to promote persistence and improve fracture protection.

Original languageEnglish
Pages (from-to)114-125
Number of pages12
JournalActa reumatologica portuguesa
Volume44
Issue number2
Publication statusPublished - 8 Jul 2019

Fingerprint

Postmenopausal Osteoporosis
Diphosphonates
Therapeutics
Osteoporotic Fractures
Medication Adherence
Pharmacies
Telephone
Observational Studies
Prescriptions
Cohort Studies
Interviews
Morbidity
Mortality
Population

Cite this

Torre, C., Guerreiro, J., Mendes, Z., Miranda, A., Bragança, F., Cristino, J., ... Branco, J. C. (2019). Low persistence with oral biphosphonate treatment in postmenopausal osteoporosis. Acta reumatologica portuguesa, 44(2), 114-125.
Torre, Carla ; Guerreiro, José ; Mendes, Zilda ; Miranda, Ana ; Bragança, Fátima ; Cristino, Joaquim ; Canhão, Helena ; Branco, Jaime C. / Low persistence with oral biphosphonate treatment in postmenopausal osteoporosis. In: Acta reumatologica portuguesa. 2019 ; Vol. 44, No. 2. pp. 114-125.
@article{c732a26601ef4b87b8f02d15c084ec15,
title = "Low persistence with oral biphosphonate treatment in postmenopausal osteoporosis",
abstract = "BACKGROUND: Osteoporotic fractures are a major cause of morbidity and mortality. It is recognized that persistence with medication is crucial to reach optimal clinical outcomes. We aimed to estimate the persistence level to weekly and monthly oral bisphosphonates (OBP) in women with postmenopausal osteoporosis (PMO) over 24 months from therapy initiation in a population-based setting.METHODS: Prospective observational cohort study of PMO women ≥50 years initiating OBP recruited through community pharmacies. Data were collected at baseline during face-to-face interviews. Follow-up included pharmacy records (refill dates and medication possession; cohort 1) and telephone-surveys for patients who agreed to be interviewed (cohort 2). Patients were classified as persistent if they refilled their prescription within 30 days after exhausting the time covered by their previous supply. Log-rank tests were used to compare Kaplan-Meier curves of time to non-persistence.RESULTS: Of 427 women recruited with a mean age of 65.0 years, 380 (89{\%}) agreed to be interviewed (cohort 2). Over 24-months of follow-up, 3.4{\%} (95{\%} CI: [2.0{\%}; 5.6{\%}]) of all subjects were persistent to OBP based on pharmacy records. Analysis combining both self-reported information and pharmacy records (cohort 2) showed a persistence estimate of 20.0{\%} (95{\%} CI: [16.1{\%}; 24.2{\%}]). Lower persistence was associated with more frequent OBP dosing and living alone. The most common reason for treatment discontinuation was self-reported adverse events (27.6{\%}).CONCLUSIONS: Results indicate a low level of persistence with OBP. Barriers and reasons leading to discontinuation of anti-PMO therapies should be proactively addressed to promote persistence and improve fracture protection.",
author = "Carla Torre and Jos{\'e} Guerreiro and Zilda Mendes and Ana Miranda and F{\'a}tima Bragan{\cc}a and Joaquim Cristino and Helena Canh{\~a}o and Branco, {Jaime C}",
year = "2019",
month = "7",
day = "8",
language = "English",
volume = "44",
pages = "114--125",
journal = "Acta reumatologica portuguesa",
issn = "0303-464X",
publisher = "Sociedade Portuguesa de Reumatologia",
number = "2",

}

Torre, C, Guerreiro, J, Mendes, Z, Miranda, A, Bragança, F, Cristino, J, Canhão, H & Branco, JC 2019, 'Low persistence with oral biphosphonate treatment in postmenopausal osteoporosis', Acta reumatologica portuguesa, vol. 44, no. 2, pp. 114-125.

Low persistence with oral biphosphonate treatment in postmenopausal osteoporosis. / Torre, Carla; Guerreiro, José; Mendes, Zilda; Miranda, Ana; Bragança, Fátima; Cristino, Joaquim; Canhão, Helena; Branco, Jaime C.

In: Acta reumatologica portuguesa, Vol. 44, No. 2, 08.07.2019, p. 114-125.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Low persistence with oral biphosphonate treatment in postmenopausal osteoporosis

AU - Torre, Carla

AU - Guerreiro, José

AU - Mendes, Zilda

AU - Miranda, Ana

AU - Bragança, Fátima

AU - Cristino, Joaquim

AU - Canhão, Helena

AU - Branco, Jaime C

PY - 2019/7/8

Y1 - 2019/7/8

N2 - BACKGROUND: Osteoporotic fractures are a major cause of morbidity and mortality. It is recognized that persistence with medication is crucial to reach optimal clinical outcomes. We aimed to estimate the persistence level to weekly and monthly oral bisphosphonates (OBP) in women with postmenopausal osteoporosis (PMO) over 24 months from therapy initiation in a population-based setting.METHODS: Prospective observational cohort study of PMO women ≥50 years initiating OBP recruited through community pharmacies. Data were collected at baseline during face-to-face interviews. Follow-up included pharmacy records (refill dates and medication possession; cohort 1) and telephone-surveys for patients who agreed to be interviewed (cohort 2). Patients were classified as persistent if they refilled their prescription within 30 days after exhausting the time covered by their previous supply. Log-rank tests were used to compare Kaplan-Meier curves of time to non-persistence.RESULTS: Of 427 women recruited with a mean age of 65.0 years, 380 (89%) agreed to be interviewed (cohort 2). Over 24-months of follow-up, 3.4% (95% CI: [2.0%; 5.6%]) of all subjects were persistent to OBP based on pharmacy records. Analysis combining both self-reported information and pharmacy records (cohort 2) showed a persistence estimate of 20.0% (95% CI: [16.1%; 24.2%]). Lower persistence was associated with more frequent OBP dosing and living alone. The most common reason for treatment discontinuation was self-reported adverse events (27.6%).CONCLUSIONS: Results indicate a low level of persistence with OBP. Barriers and reasons leading to discontinuation of anti-PMO therapies should be proactively addressed to promote persistence and improve fracture protection.

AB - BACKGROUND: Osteoporotic fractures are a major cause of morbidity and mortality. It is recognized that persistence with medication is crucial to reach optimal clinical outcomes. We aimed to estimate the persistence level to weekly and monthly oral bisphosphonates (OBP) in women with postmenopausal osteoporosis (PMO) over 24 months from therapy initiation in a population-based setting.METHODS: Prospective observational cohort study of PMO women ≥50 years initiating OBP recruited through community pharmacies. Data were collected at baseline during face-to-face interviews. Follow-up included pharmacy records (refill dates and medication possession; cohort 1) and telephone-surveys for patients who agreed to be interviewed (cohort 2). Patients were classified as persistent if they refilled their prescription within 30 days after exhausting the time covered by their previous supply. Log-rank tests were used to compare Kaplan-Meier curves of time to non-persistence.RESULTS: Of 427 women recruited with a mean age of 65.0 years, 380 (89%) agreed to be interviewed (cohort 2). Over 24-months of follow-up, 3.4% (95% CI: [2.0%; 5.6%]) of all subjects were persistent to OBP based on pharmacy records. Analysis combining both self-reported information and pharmacy records (cohort 2) showed a persistence estimate of 20.0% (95% CI: [16.1%; 24.2%]). Lower persistence was associated with more frequent OBP dosing and living alone. The most common reason for treatment discontinuation was self-reported adverse events (27.6%).CONCLUSIONS: Results indicate a low level of persistence with OBP. Barriers and reasons leading to discontinuation of anti-PMO therapies should be proactively addressed to promote persistence and improve fracture protection.

M3 - Article

VL - 44

SP - 114

EP - 125

JO - Acta reumatologica portuguesa

JF - Acta reumatologica portuguesa

SN - 0303-464X

IS - 2

ER -

Torre C, Guerreiro J, Mendes Z, Miranda A, Bragança F, Cristino J et al. Low persistence with oral biphosphonate treatment in postmenopausal osteoporosis. Acta reumatologica portuguesa. 2019 Jul 8;44(2):114-125.